论文部分内容阅读
乙型肝炎病毒感染无症状乙肝抗原(HBsAg)携带者在我国达一亿人以上,分布广、携带时间长,对健康人群构成严重威胁,迄今尚无有效简便的防治方法。1984年以来我们应用8490免疫治疗剂局部皮肤涂药法,在南京军区福州总医院工作人员中选择HBsAg持续携带6个月以上、GPT正常者72例,随机分成治疗组和对照组进行观察,其中男52例,女20例;7～15岁儿童13例,成人59例。方法:8490免疫治疗剂为我们新近研究成功的左旋咪唑新剂型,治疗组成人一次涂药量1.0～1.5ml,7～15岁儿童减半。将药液直接滴在手臂或小腿部健康皮肤上,边滴边用安瓿口涂布均匀,每周一次,连续6个月,对照组用不合左旋咪唑(其他溶媒、载体
Hepatitis B virus infection Asymptomatic hepatitis B antigen (HBsAg) carriers in China reached 100000000 people, widely distributed, carrying a long time, pose a serious threat to the health of people, so far there is no effective and easy control methods. Since 1984, we applied 8490 immunotherapeutic topical dermal application method and selected HBsAg in our staff in Fuzhou General Hospital of Nanjing Military Region for continuous persistence of more than 6 months and 72 cases of normal GPT, and were randomly divided into treatment group and control group, in which 52 males and 20 females; 13 children aged 7-15 years, 59 adults. Methods: The 8490 immunotherapeutic agent was a new levamisole formulation newly researched successfully in our group. The treatment group was given a dose of 1.0-1.5ml once and half of the children aged 7-15 years. The liquid drops directly on the health of the arm or lower leg skin, while dropping ampoule mouth evenly coated once a week for 6 months, the control group with levamisole (other vehicles, carriers